BetterLife Pharma Inc. (BETR.CN)
CAD 0.1
(5.26%)
CAD 0.1
(5.26%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.88 Million CAD | 67.96% |
| 2022 | -9.01 Million CAD | 25.85% |
| 2021 | -12.15 Million CAD | 66.55% |
| 2020 | -36.35 Million CAD | -85.57% |
| 2019 | -19.58 Million CAD | -111.66% |
| 2018 | -9.25 Million CAD | -6090.3% |
| 2017 | -149.5 Thousand CAD | 98.18% |
| 2016 | -8.22 Million CAD | 31.39% |
| 2015 | -11.99 Million CAD | -1096.03% |
| 2014 | -1 Million CAD | -32.98% |
| 2013 | -753.87 Thousand CAD | -320.8% |
| 2012 | 341.42 Thousand CAD | -75.92% |
| 2011 | 1.41 Million CAD | 146.9% |
| 2010 | -3.02 Million CAD | -2416.41% |
| 2009 | -120.13 Thousand CAD | 81.62% |
| 2008 | -653.76 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.94 Million CAD | -49.46% |
| 2024 Q2 | -1.43 Million CAD | 26.06% |
| 2023 Q3 | -195.45 Thousand CAD | 80.82% |
| 2023 Q2 | -1.01 Million CAD | -5.77% |
| 2023 Q1 | -963.66 Thousand CAD | -331.77% |
| 2023 Q4 | -1.3 Million CAD | -566.4% |
| 2023 FY | -2.88 Million CAD | 67.96% |
| 2022 Q4 | -223.19 Thousand CAD | 95.23% |
| 2022 Q1 | -2.98 Million CAD | 24.11% |
| 2022 Q2 | -1.12 Million CAD | 62.43% |
| 2022 Q3 | -4.67 Million CAD | -316.72% |
| 2022 FY | -9.01 Million CAD | 25.85% |
| 2021 Q2 | -3.56 Million CAD | -46.08% |
| 2021 FY | -12.15 Million CAD | 66.55% |
| 2021 Q1 | -2.44 Million CAD | 91.12% |
| 2021 Q3 | -2.2 Million CAD | 38.15% |
| 2021 Q4 | -3.93 Million CAD | -78.39% |
| 2020 Q2 | -1.56 Million CAD | -511.99% |
| 2020 Q1 | 378.96 Thousand CAD | 103.55% |
| 2020 Q4 | -27.5 Million CAD | -274.27% |
| 2020 FY | -36.35 Million CAD | -85.57% |
| 2020 Q3 | -7.34 Million CAD | -370.71% |
| 2019 FY | -19.58 Million CAD | -111.66% |
| 2019 Q1 | -1.87 Million CAD | -157.38% |
| 2019 Q4 | -10.67 Million CAD | -311.47% |
| 2019 Q3 | -2.59 Million CAD | 40.9% |
| 2019 Q2 | -4.38 Million CAD | -134.12% |
| 2018 Q2 | -1.84 Million CAD | 11.67% |
| 2018 Q1 | -2.08 Million CAD | -405.24% |
| 2018 Q4 | -728.16 Thousand CAD | 83.57% |
| 2018 Q3 | -4.43 Million CAD | -140.45% |
| 2018 FY | -9.25 Million CAD | -6090.3% |
| 2017 Q1 | -436.4 Thousand CAD | 51.19% |
| 2017 FY | -149.5 Thousand CAD | 98.18% |
| 2017 Q4 | -412.96 Thousand CAD | -160.65% |
| 2017 Q3 | 680.87 Thousand CAD | 9932.5% |
| 2017 Q2 | -6924.72 CAD | 98.41% |
| 2016 Q2 | -1.54 Million CAD | 63.17% |
| 2016 Q3 | -1.28 Million CAD | 16.84% |
| 2016 FY | -8.22 Million CAD | 31.39% |
| 2016 Q4 | -894.04 Thousand CAD | 30.21% |
| 2016 Q1 | -4.18 Million CAD | 45.02% |
| 2015 Q4 | -7.6 Million CAD | -73621.67% |
| 2015 FY | -11.99 Million CAD | -1096.03% |
| 2015 Q2 | -2.93 Million CAD | -101.47% |
| 2015 Q1 | -1.45 Million CAD | -63.94% |
| 2015 Q3 | -10.32 Thousand CAD | 99.65% |
| 2014 Q2 | -36.46 Thousand CAD | -140.17% |
| 2014 Q1 | 90.76 Thousand CAD | 264.65% |
| 2014 FY | -1 Million CAD | -32.98% |
| 2014 Q4 | -889.11 Thousand CAD | -430.12% |
| 2014 Q3 | -167.72 Thousand CAD | -360.01% |
| 2013 Q4 | -55.12 Thousand CAD | 90.84% |
| 2013 Q2 | -48.2 Thousand CAD | 1.66% |
| 2013 Q3 | -601.53 Thousand CAD | -1147.94% |
| 2013 Q1 | -49.01 Thousand CAD | 28.87% |
| 2013 FY | -753.87 Thousand CAD | -320.8% |
| 2012 Q4 | -68.91 Thousand CAD | -13.62% |
| 2012 FY | 341.42 Thousand CAD | -75.92% |
| 2012 Q1 | 593.9 Thousand CAD | 161.84% |
| 2012 Q2 | -122.91 Thousand CAD | -120.7% |
| 2012 Q3 | -60.65 Thousand CAD | 50.66% |
| 2011 Q1 | 2.11 Million CAD | 172.1% |
| 2011 Q3 | 129.57 Thousand CAD | -3.03% |
| 2011 Q4 | -960.35 Thousand CAD | -841.17% |
| 2011 FY | 1.41 Million CAD | 146.9% |
| 2011 Q2 | 133.62 Thousand CAD | -93.68% |
| 2010 Q2 | -42.52 Thousand CAD | -57.19% |
| 2010 Q1 | -27.05 Thousand CAD | -56.75% |
| 2010 Q4 | -2.93 Million CAD | -14431.36% |
| 2010 FY | -3.02 Million CAD | -2416.41% |
| 2010 Q3 | -20.18 Thousand CAD | 52.53% |
| 2009 Q2 | -75.96 Thousand CAD | -493.3% |
| 2009 Q3 | -14.11 Thousand CAD | 81.42% |
| 2009 FY | -120.13 Thousand CAD | 81.62% |
| 2009 Q4 | -17.25 Thousand CAD | -22.26% |
| 2009 Q1 | -12.8 Thousand CAD | 0.0% |
| 2008 FY | -653.76 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -6.78 Million CAD | 57.396% |
| Asep Medical Holdings Inc | -8.22 Million CAD | 64.885% |
| BioVaxys Technology Corp. | -7.68 Million CAD | 62.418% |
| ChitogenX Inc. | -1.55 Million CAD | -85.909% |
| Rapid Dose Therapeutics Corp. | -4.3 Million CAD | 32.915% |
| Defence Therapeutics Inc. | -13.19 Million CAD | 78.102% |
| Entheon Biomedical Corp. | -300 Thousand CAD | -863.007% |
| Gemina Laboratories Ltd. | -5.21 Million CAD | 44.62% |
| Glow Lifetech Corp. | -1.64 Million CAD | -75.56% |
| Lexston Life Sciences Corp. | -867.71 Thousand CAD | -232.948% |
| Pharmala Biotech Holdings Inc. | -779.81 Thousand CAD | -270.478% |
| Doseology Sciences Inc. | -339.84 Thousand CAD | -750.095% |
| MYND Life Sciences Inc. | -1.51 Million CAD | -90.336% |
| Nova Mentis Life Science Corp. | -1.22 Million CAD | -135.951% |
| PharmaTher Holdings Ltd. | -3.11 Million CAD | 7.264% |
| PreveCeutical Medical Inc. | -1.27 Million CAD | -126.685% |
| Telescope Innovations Corp. | -5.72 Million CAD | 49.557% |